BIOMAT Database Logo BIOMAT Database Logo

Synergistic antiproliferative effect of interferon alpha and azidothymidine in chronic myelogenous leukemia. 1991

Z Estrov, and M Talpaz, and T C Chou, and R Kurzrock, and M Blake, and J U Gutterman
Department of Clinical Immunology and Biological Therapy, University of Texas MD Anderson Cancer Center, Houston 77030.

The possible synergistic interaction between azidothymidine (AZT) and interferon alpha (rIFN-alpha 2a) in the treatment of chronic myelogenous leukemia (CML) was studied in vitro using marrow or peripheral blood hematopoietic progenitors from 10 patients with CML in the mixed (CFU-GEMM) colony culture assay. Used singly, either agent inhibited erythroid (BFU-E) and granulocyte-macrophage (CFU-GM) CML hematopoietic progenitor proliferation in a dose-dependent fashion, with the inhibitory effect being more pronounced on BFU-E than on CFU-GM colony-forming cells. The combination of both drugs in therapeutic concentrations exerted a significant synergistic inhibition on CML stem cells as assessed by the median-effect principle and isobologram equation analysis. A suboptimal dose of AZT (0.5 mumol/l) synergistically augmented the effect of rIFN-alpha 2a whereas an inactive dose of 10 U/ml rIFN-alpha 2a similarly enhanced the CML stem cell growth inhibition exerted by AZT. Our data indicate that AZT may augment the already established therapeutic benefits of IFN-alpha in CML.

UI MeSH Term Description Entries
D007370 Interferon Type I Interferon secreted by leukocytes, fibroblasts, or lymphoblasts in response to viruses or interferon inducers other than mitogens, antigens, or allo-antigens. They include alpha- and beta-interferons (INTERFERON-ALPHA and INTERFERON-BETA). Interferons Type I,Type I Interferon,Type I Interferons,Interferon, Type I,Interferons, Type I
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004357 Drug Synergism The action of a drug in promoting or enhancing the effectiveness of another drug. Drug Potentiation,Drug Augmentation,Augmentation, Drug,Augmentations, Drug,Drug Augmentations,Drug Potentiations,Drug Synergisms,Potentiation, Drug,Potentiations, Drug,Synergism, Drug,Synergisms, Drug
D005260 Female Females
D006410 Hematopoiesis The development and formation of various types of BLOOD CELLS. Hematopoiesis can take place in the BONE MARROW (medullary) or outside the bone marrow (HEMATOPOIESIS, EXTRAMEDULLARY). Hematopoiesis, Medullary,Haematopoiesis,Medullary Hematopoiesis
D006412 Hematopoietic Stem Cells Progenitor cells from which all blood cells derived. They are found primarily in the bone marrow and also in small numbers in the peripheral blood. Colony-Forming Units, Hematopoietic,Progenitor Cells, Hematopoietic,Stem Cells, Hematopoietic,Hematopoietic Progenitor Cells,Cell, Hematopoietic Progenitor,Cell, Hematopoietic Stem,Cells, Hematopoietic Progenitor,Cells, Hematopoietic Stem,Colony Forming Units, Hematopoietic,Colony-Forming Unit, Hematopoietic,Hematopoietic Colony-Forming Unit,Hematopoietic Colony-Forming Units,Hematopoietic Progenitor Cell,Hematopoietic Stem Cell,Progenitor Cell, Hematopoietic,Stem Cell, Hematopoietic,Unit, Hematopoietic Colony-Forming,Units, Hematopoietic Colony-Forming
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

Z Estrov, and M Talpaz, and T C Chou, and R Kurzrock, and M Blake, and J U Gutterman
[Interferon-alpha therapy in chronic myelogenous leukemia].
April 2000, [Rinsho ketsueki] The Japanese journal of clinical hematology,
Z Estrov, and M Talpaz, and T C Chou, and R Kurzrock, and M Blake, and J U Gutterman
Synergistic antiproliferative effect of recombinant interferon-gamma with recombinant interferon-alpha on chronic myelogenous leukemia hematopoietic progenitor cells (CFU-GEMM, CFU-Mk, BFU-E, and CFU-GM).
October 1988, Blood,
Z Estrov, and M Talpaz, and T C Chou, and R Kurzrock, and M Blake, and J U Gutterman
Interferon-alpha therapy for chronic myelogenous leukemia.
October 1995, The American journal of medicine,
Z Estrov, and M Talpaz, and T C Chou, and R Kurzrock, and M Blake, and J U Gutterman
Interferon alpha in the treatment of chronic myelogenous leukemia.
January 1998, Archivum immunologiae et therapiae experimentalis,
Z Estrov, and M Talpaz, and T C Chou, and R Kurzrock, and M Blake, and J U Gutterman
Synergistic antiproliferative effect of interferons and azidothymidine on HL60 cells.
March 1992, Chemical & pharmaceutical bulletin,
Z Estrov, and M Talpaz, and T C Chou, and R Kurzrock, and M Blake, and J U Gutterman
Chronic myelogenous leukemia: does interferon alpha prolong life?
February 1996, Leukemia,
Z Estrov, and M Talpaz, and T C Chou, and R Kurzrock, and M Blake, and J U Gutterman
Pericarditis during interferon-alpha therapy in chronic myelogenous leukemia.
January 1996, Haematologica,
Z Estrov, and M Talpaz, and T C Chou, and R Kurzrock, and M Blake, and J U Gutterman
Immunological effects of interferon-alpha on chronic myelogenous leukemia.
December 2003, Leukemia & lymphoma,
Z Estrov, and M Talpaz, and T C Chou, and R Kurzrock, and M Blake, and J U Gutterman
Effect of interferon-alpha therapy on bone marrow fibrosis in chronic myelogenous leukemia.
January 1998, Leukemia,
Z Estrov, and M Talpaz, and T C Chou, and R Kurzrock, and M Blake, and J U Gutterman
Effect of interferon-alpha on chromosome abnormalities in treated chronic myelogenous leukemia patients.
September 2004, Cancer genetics and cytogenetics,
Copied contents to your clipboard!